

Taurolidine-citrate vs heparin as catheter lock solutions in paediatric patients

Submission date 07/12/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/01/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 08/02/2011	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Uwe Querfeld

Contact details
Department of Pediatric Nephrology
Charité Universitätsmedizin Berlin
Berlin
Germany
13353

Additional identifiers

Protocol serial number
EA2/084/06

Study information

Scientific Title

Acronym
Taurolock study

Study objectives

Use of taurolidine-citrate for catheter locking leads to a significant reduction of bacterial growth and catheter-related infections in paediatric patients with implanted central venous catheters

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received by local ethics committee (Ethikkommission 2 am Campus Virchow Klinikum) on 29 September 2006 (ref: EA2/084/06).

Study design

Randomized prospective study in pediatric hospital with stratification for patients treated in renal/oncology/hematology departments

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Catheter-related infections

Interventions

Taurolidine-citrate vs heparin as catheter lock solutions

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Bacterial growth/biofilm formation in removed catheters

Key secondary outcome(s)

Catheter-related infections, catheter occlusions

Completion date

31/12/2007

Eligibility**Key inclusion criteria**

Paediatric patients with newly implanted central venous catheters

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

Not Specified

Key exclusion criteria

Bacteremia/sepsis ongoing; allergy against heparin or taurolidine

Date of first enrolment

01/01/2007

Date of final enrolment

31/12/2007

Locations**Countries of recruitment**

Germany

Study participating centre

Department of Pediatric Nephrology

Berlin

Germany

13353

Sponsor information**Organisation**

Tauropharm (Germany)

Funder(s)**Funder type**

Industry

Funder Name

Tauropharm GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration